Kodai Capital Management LP Takes Position in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• Kodai Capital Management LP invested approximately $1.49 million in Agios Pharmaceuticals, acquiring 50,692 shares, representing about 0.09% ownership in the company.
• Agios Pharmaceuticals' stock price decreased by 1.2%, with recent company performance reflecting a loss of $1.93 EPS for the last quarter, missing analyst expectations.
• Wall Street analysts have set a consensus rating of "Moderate Buy" for Agios Pharmaceuticals, with target prices ranging between $51.00 and $65.00.

Kodai Capital Management LP purchased a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 50,692 shares of the biopharmaceutical company's stock, valued at approximately $1,485,000. Kodai Capital Management LP owned about 0.09% of Agios Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of AGIO. GF Fund Management CO. LTD. purchased a new stake in Agios Pharmaceuticals in the 4th quarter valued at $39,000. CWM LLC raised its position in Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after buying an additional 996 shares during the last quarter. PNC Financial Services Group Inc. raised its position in Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after buying an additional 499 shares during the last quarter. GAMMA Investing LLC raised its position in Agios Pharmaceuticals by 9,296.6% in the 1st quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock valued at $240,000 after buying an additional 8,088 shares during the last quarter. Finally, Commerce Bank purchased a new stake in Agios Pharmaceuticals in the 1st quarter valued at $240,000.

Analyst Upgrades and Downgrades

A number of research firms recently commented on AGIO. Wall Street Zen lowered Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Bank of America decreased their target price on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research report on Tuesday, July 22nd. Finally, Scotiabank decreased their target price on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research report on Monday, July 28th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $56.33.

Agios Pharmaceuticals Trading Down 11.9%

Shares of AGIO stock traded down $4.83 on Thursday, hitting $35.79. 1,586,635 shares of the stock were exchanged, compared to its average volume of 708,507. The firm has a market capitalization of $2.08 billion, a PE ratio of 3.26 and a beta of 0.87. Agios Pharmaceuticals, Inc. has a one year low of $23.42 and a one year high of $62.58. The firm's 50 day moving average is $37.48 and its two-hundred day moving average is $33.17.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%.The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.46 million. On average, sell-side analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insiders Place Their Bets

In other Agios Pharmaceuticals news, CEO Brian Goff sold 18,700 shares of the firm's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $33.54, for a total value of $627,198.00. Following the completion of the transaction, the chief executive officer owned 105,401 shares in the company, valued at $3,535,149.54. This trade represents a 15.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Tsveta Milanova sold 2,770 shares of Agios Pharmaceuticals stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $92,905.80. Following the sale, the insider owned 26,122 shares of the company's stock, valued at approximately $876,131.88. This trade represents a 9.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 57,448 shares of company stock worth $2,026,141 over the last quarter. Insiders own 4.93% of the company's stock.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.